Oculis Published P-II Study Results of Licaminlimab (OCS-02) for the Treatment of Severe Dry Eye Disease in Clinical Ophthalmology
- The P-II study evaluates the effect of licaminlimab vs vehicle in 514 patients with sev. dry eye disease
- The trial meets its 1EPs & 2EPs i.e., the therapy showed superiority over a vehicle for the relief of ocular discomfort, changes from baseline to 29 Days in the global ocular discomfort score (-7.9 vs -3.6), improvement in global ocular discomfort score >20 from baseline 29 Day (17.9% vs 4.7%), was well tolerated with no increase in intra-ocular pressure & no other safety issues
- The P-IIb study of OCS-02 is expected to be initiated in the coming months for DED & uveitis. OCS-01 is also being evaluated in an ongoing P-III trial for DMA & inflammation and pain while the POC trial of OCS-05 in acute optic neuritis
Ref: GlobeNewswire | Image: Oculis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.